Halozyme Therapeutics (HALO) Assets Average (2011 - 2026)
Halozyme Therapeutics (HALO) posted quarterly Assets Average of $2.6 billion for Q1 2026, up 22.02% year-over-year from $2.1 billion in Q1 2025, and up 9.51% quarter-over-quarter from $2.4 billion in Q4 2025.
Halozyme Therapeutics (HALO) Assets Average (2011 - 2026) Analysis & Trends
Halozyme Therapeutics (HALO) has reported Assets Average for 16 consecutive years, with $2.6 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Assets Average rose 22.02% year-over-year to $2.6 billion; the TTM figure through Mar 2026 stood at $2.6 billion (up 22.02% YoY), while the FY2025 annual figure was $2.3 billion, up 20.86% from the prior year.
- Assets Average grew to $2.6 billion in Q1 2026 per HALO's latest filing, from $2.4 billion in the prior quarter.
- Across five years, Assets Average topped out at $2.6 billion in Q1 2026 and bottomed at $1.1 billion in Q1 2022.
- Historically, Assets Average has averaged $1.9 billion across 5 years, with a median of $1.9 billion in 2022.
- Annual changes were most pronounced in 2022 — Assets Average surged 64.88% — and 2023, when it dropped 2.16%.
- Halozyme Therapeutics' Assets Average stood at $1.9 billion in 2022, then slipped by 2.16% to $1.8 billion in 2023, then climbed by 15.32% to $2.1 billion in 2024, then climbed by 13.51% to $2.4 billion in 2025, then climbed by 9.51% to $2.6 billion in 2026.
- Business Quant data shows HALO's Assets Average at $2.6 billion in Q1 2026, $2.4 billion in Q4 2025, and $2.1 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 3.29 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 8.86 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 16.08 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 19.82 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 5.34 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 2.09 Bn |
| 10 | Halozyme Therapeutics | 11.25 Bn | 11.02 Bn | 401.83 Mn | 2.63 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 2.63 Bn |
| Mar 31, 2026 | 2.60 Bn |
| Dec 31, 2025 | 2.37 Bn |
| Sep 30, 2025 | 2.14 Bn |
| Jun 30, 2025 | 2.13 Bn |
| Mar 31, 2025 | 2.13 Bn |
| Dec 31, 2024 | 2.09 Bn |
| Sep 30, 2024 | 2.04 Bn |
| Jun 30, 2024 | 1.91 Bn |
| Mar 31, 2024 | 1.79 Bn |
| Dec 31, 2023 | 1.81 Bn |
| Sep 30, 2023 | 1.85 Bn |
| Jun 30, 2023 | 1.75 Bn |
| Mar 31, 2023 | 1.77 Bn |
| Dec 31, 2022 | 1.85 Bn |
| Sep 30, 2022 | 1.82 Bn |
| Jun 30, 2022 | 1.47 Bn |
| Mar 31, 2022 | 1.13 Bn |
| Dec 31, 2021 | 1.14 Bn |
| Sep 30, 2021 | 1.11 Bn |